Atrial Fibrillation Ablation

Boston Scientific announced it received FDA approval for its navigation-enabled ablation catheter for the treatment of paroxysmal atrial fibrillation and 510(k) clearance for new imaging software for its pulsed field ablation system.

Pulmonary vein isolation was associated with genuine improvements in patients with atrial fibrillation at 6 months that cannot be attributed to a placebo effect, researchers reported at the European Society of Cardiology Congress.

In the United States, the COVID-19 pandemic was associated with more than 50,000 lost electrophysiology procedures totaling more than $7 billion in revenue in 2020, researchers reported in HeartRhythm.

A pulsed field ablation system was associated with low rates of safety events and high rates of efficacy for patients with paroxysmal atrial fibrillation at 12 months, according to the results of the admIRE pivotal trial.

In patients with atrial fibrillation who had ablation, those assigned a Mediterranean diet enriched with extra-virgin olive oil were less likely to have arrhythmia recurrence than those with no dietary restrictions, researchers reported.

In patients with type 2 diabetes who underwent ablation for atrial fibrillation, those taking a GLP-1 receptor agonist had lower risk for AF recurrence, mortality and other outcomes, researchers reported at Heart Rhythm 2024.

Catheter ablation for atrial fibrillation was associated with lower incidence of hospitalization for worsening HF vs. drug therapy in patients with HF with preserved ejection fraction, researchers reported.

Medtronic announced the FDA approved its pulsed field ablation system for treatment of both paroxysmal and persistent atrial fibrillation via pulmonary vein isolation.

For millions of patients who live with atrial fibrillation, early detection and treatment are essential because research shows that early, intensive management of AF reduces stroke, hospitalization and heart failure.

Ostial and antral pulmonary vein isolation, ablation plus posterior wall isolation and cryoablation all demonstrated comparable success in treating persistent atrial fibrillation, according to a post hoc analysis of the DECAAF II trial.